Lv1
12 积分 2024-09-09 加入
Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants
3天前
已完结
Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations
5天前
已完结
A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
7天前
已完结
Predictivity/Translatability of Toxicities Observed in Nonclinical Toxicology Studies to Clinical Safety Outcomes in Drug Development: Case Examples
14天前
已完结
Translational Challenges From Nonclinical to Clinical Program: Case Study Examples
14天前
已完结
Health policy and public health implications of obesity in China
28天前
已完结
A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease
28天前
已完结
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
29天前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
30天前
已完结
Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes
1个月前
已完结
皖公网安备34019202002308
